Absorption, Metabolism and Excretion of 14C-olorofim in Man (hAME)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04039880|
Recruitment Status : Completed
First Posted : July 31, 2019
Last Update Posted : November 13, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Invasive Fungal Infections||Drug: Olorofim||Phase 1|
Subjects will be screened up to 28 days prior to dosing and eligible subjects will be admitted to the Clinical Research Unit (CRU) on the day prior to dosing (Day-1). Each subject will be dosed on the morning of Day 1 after an overnight fast.
Subjects will remain resident in the CRU up to 336 h post-dose (Day 15), with whole blood, plasma, urine and faeces collected throughout this period. There may be up to two further 24 h residency periods (Days 21 to 22 and Days 28 to 29) for collection of plasma, urine and faeces if discharge criteria are not met.
Cohorts B1 and B2:
Subjects will remain resident in the CRU up to 96 h post-dose (Day 5) for collection of plasma, urine, faeces and bile. Subjects will return for a short follow-up visit on Day 10. Cohort B1 subjects will have bile sampling up to 6 h postdose and Cohort B2 subjects will have bile sampling up to 12 h postdose. Cohort B divided into 2 sub-cohorts for logistical reasons only.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Olorofim Administered Via the Oral Route to Healthy Male Subjects|
|Actual Study Start Date :||July 30, 2019|
|Actual Primary Completion Date :||September 30, 2019|
|Actual Study Completion Date :||September 30, 2019|
Experimental: Cohort A (mass balance)
evaluation of mass balance and metabolite profiling
single oral dose (120 mg, 3.7 MBq)
Other Name: F901318
Experimental: Cohort B (biliary evaluation)
evaluation of biliary elimination
single oral dose (120 mg, 3.7 MBq)
Other Name: F901318
- Mass balance [ Time Frame: 28 days ]% dose recovered in urine and faeces
- Metabolite profiling [ Time Frame: 15 days ]number of metabolites in plasma, urine and faeces > 10% of circulating radioactivity
- biliary elimination [ Time Frame: 5 days ]radioactivity present in bile (ug equiv/g)
- Maximum plasma concentration (Cmax) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
- time of maximum plasma concentration (Tmax) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
- elimination half life (t1/2) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
- Area under plasma concentration curve (AUC) for olorofim, F902412 and total radioactivity [ Time Frame: 15 days ]
- Number of subjects with treatment-related adverse events [ Time Frame: 28 days ]
- Number of subjects with clinically significant change from baseline in vital signs, laboratory parameters, and electrocardiogram findings [ Time Frame: 28 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 55 Years (Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||Yes|
- healthy males age 18 to 55 years of age with body mass index of 18 to 30 kg/m2 (inclusive), and a body weight of 50 to 100 kg (inclusive).
- Subjects must be in good health as determined by a medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is NOT acceptable).
- Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools per day).
- Subjects with or history of clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatry, respiratory, metabolic, endocrine, ocular haematological or other major disorders as determined by the investigator
- Subjects who have received any prescribed systemic or topical medication within 14 days of the dose administration
- Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the dose administration
- Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of the dose administration
- Current smokers and those who have smoked or used nicotine containing products (eg electronic cigarettes) within the 3 months prior to check-in.
- Radiation exposure, including that from the present study exceeding 1 mSv in the last 12 months or 5 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04039880
|PRA Health Sciences|
|Groningen, Netherlands, 9728|
|Principal Investigator:||Jan Jaap van Lier, MD||PRA|
|Responsible Party:||F2G Biotech GmbH|
|Other Study ID Numbers:||
|First Posted:||July 31, 2019 Key Record Dates|
|Last Update Posted:||November 13, 2019|
|Last Verified:||August 2019|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Invasive Fungal Infections
Bacterial Infections and Mycoses